Ignite Creation Date:
2024-07-17 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06470971
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-06-17
Brief Title:
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer CIRES Trial
Sponsor:
Organization:
Ohio State University Comprehensive Cancer Center